J12 The perspective program: evaluating the effect of SAGE-718 on cognitive function in patients wit...
J12 The perspective program: evaluating the effect of SAGE-718 on cognitive function in patients with Huntington’s disease
About this item
Full title
Author / Creator
Publisher
London: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
BackgroundCognitive impairment is a key driver of disability in patients with early-stage Huntington’s disease (HD). SAGE-718 is an investigational NMDA receptor positive allosteric modulator that has been generally well tolerated and associated with improved cognitive performance in patients with HD and other neurodegenerative diseases in clinical...
Alternative Titles
Full title
J12 The perspective program: evaluating the effect of SAGE-718 on cognitive function in patients with Huntington’s disease
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2724388506
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2724388506
Other Identifiers
ISSN
0022-3050
E-ISSN
1468-330X
DOI
10.1136/jnnp-2022-ehdn.262
